510758-19-7Relevant articles and documents
Highly selective and wash-free visualization of resistant bacteria with a relebactam-derived fluorogenic probe
Chen, Yefeng,Xu, Minqiu,Xu, Weipan,Song, Heng,Hu, Liqiang,Xue, Shuyuan,Zhang, Shuangzhan,Qian, Xiana,Xie, Hexin
, p. 9919 - 9922 (2019)
Reported herein is a relebactam-derived fluorogenic reagent for covalent labeling of serine β-lactamases (SBLs), which are the major causes of bacterial resistance to β-lactam antibiotics. This highly selective imaging reagent generates over 300-fold stronger near-infrared fluorescence signals upon covalently bonding to SBLs, allowing wash-free visualization of live antimicrobial-resistant bacteria.
Tuning the moenomycin pharmacophore to enable discovery of bacterial cell wall synthesis inhibitors
Gampe, Christian M.,Tsukamoto, Hirokazu,Doud, Emma H.,Walker, Suzanne,Kahne, Daniel
supporting information, p. 3776 - 3779 (2013/04/23)
New antibiotic drugs need to be identified to address rapidly developing resistance of bacterial pathogens to common antibiotics. The natural antibiotic moenomycin A is the prototype for compounds that bind to bacterial peptidoglycan glycosyltransferases
CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS
-
Paragraph 00154; 00155, (2013/10/22)
The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).
METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS
-
Paragraph 00223; 00233-00234, (2013/10/22)
The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).